285 related articles for article (PubMed ID: 28456943)
1. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
[TBL] [Abstract][Full Text] [Related]
2. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
3. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
Stock I
Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
[TBL] [Abstract][Full Text] [Related]
4. Oral and intravenous fosfomycin in complicated urinary tract infections.
López-Montesinos I; Horcajada JP
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
[TBL] [Abstract][Full Text] [Related]
5. Potential of fosfomycin in treating multidrug-resistant infections in children.
Williams PC
J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
[TBL] [Abstract][Full Text] [Related]
6. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238
[TBL] [Abstract][Full Text] [Related]
7. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
Darlow CA; da Costa RMA; Ellis S; Franceschi F; Sharland M; Piddock L; Das S; Hope W
Paediatr Drugs; 2021 Sep; 23(5):465-484. PubMed ID: 34435316
[TBL] [Abstract][Full Text] [Related]
8. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
[TBL] [Abstract][Full Text] [Related]
9. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
Dimopoulos G; Koulenti D; Parker SL; Roberts JA; Arvaniti K; Poulakou G
Expert Rev Anti Infect Ther; 2019 Mar; 17(3):201-210. PubMed ID: 30668931
[TBL] [Abstract][Full Text] [Related]
10. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
Reffert JL; Smith WJ
Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
[TBL] [Abstract][Full Text] [Related]
11. Inadequate use of antibiotics and increase in neonatal sepsis caused by resistant bacteria related to health care assistance: a systematic review.
Silva ACB; Anchieta LM; Lopes MFP; Romanelli RMC
Braz J Infect Dis; 2018; 22(4):328-337. PubMed ID: 30125532
[TBL] [Abstract][Full Text] [Related]
12. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.
Parker S; Lipman J; Koulenti D; Dimopoulos G; Roberts JA
Int J Antimicrob Agents; 2013 Oct; 42(4):289-93. PubMed ID: 23880170
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
[TBL] [Abstract][Full Text] [Related]
14. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.
Traunmüller F; Popovic M; Konz KH; Vavken P; Leithner A; Joukhadar C
Clin Pharmacokinet; 2011 Aug; 50(8):493-503. PubMed ID: 21740073
[TBL] [Abstract][Full Text] [Related]
15. Fosfomycin in the pediatric setting: Evidence and potential indications.
Baquero-Artigao F; Del Rosal Rabes T
Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
[TBL] [Abstract][Full Text] [Related]
17. [Monural--new antibiotic with single intake for treatment of acute cystitis].
Akush Ginekol (Sofiia); 2008; 47(4):56. PubMed ID: 19227768
[No Abstract] [Full Text] [Related]
18. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
Darlow CA; Parrott N; Peck RW; Hope W
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):464-475. PubMed ID: 38108548
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
Obiero CW; Williams P; Murunga S; Thitiri J; Omollo R; Walker AS; Egondi T; Nyaoke B; Correia E; Kane Z; Gastine S; Kipper K; Standing JF; Ellis S; Sharland M; Berkley JA;
Arch Dis Child; 2022 Sep; 107(9):802-810. PubMed ID: 35078765
[TBL] [Abstract][Full Text] [Related]
20. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
Darlow CA; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock LJV; Das S; Hope W
J Antimicrob Chemother; 2022 Apr; 77(5):1334-1343. PubMed ID: 35170719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
